Analgesia

127.  Berger A, Kramarz P, Kopperud GS, Edelsberg J, Oster G. Economic impact of shifting the locus of care for neuropathic pain from specialists to general practitioners. Eur J Health Econ, January 2007. [Epub]

114.  Berger A, Dukes E, Edelsberg, Stacey B, Oster G. Use of tricyclic antidepressants in older patients with diabetic peripheral neuropathy. Clin J Pain, March/April 2007.

112.  Tarride J-E, Gordon A, Vera-Llonch M, Dukes E, Rousseau C. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: A Canadian perspective. Clin Ther, November 2006.

109.  Berger A, Dukes EM, Edelsberg J, Stacey BR, Oster G. Use of tricyclic antidepressants in older patients with painful neuropathies. Eur J Clin Pharmacol, September 2006.

98.  Berger A, Dukes E, Mercadante S, Oster G. Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain. Eur J Cancer Care, October 2005.

95. Vera Llonch M, Dukes E, Delea TE, Wang ST, Oster G. Treatment of peripheral neuropathic pain: A simulation model. European J Pain, June 2005.

94. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: Results from a population-based survey. J Pain, June 2005.

88.  Oster G, Berger A, Dukes E, Edelsberg J, McCarber B.  Use of potentially inappropriate pain-related medications in older adults with painful neuropathic disorders.  Am J Geriatr Pharmacother, September 2004.

84. Berger A, Dukes E, Oster G.  Clinical characteristics and economic costs of patients with painful neuropathic disorders.  J Pain, May 2004.

81. Berger A, Hoffman DL, Goodman S, Delea TE, Seifeldin R, Oster G. Therapy switching in patients receiving long-acting opioids. Ann Pharmacother, March 2004.

79. Berger A, Dukes E, McCarberg B, Liss M, Oster G. Change in opioid use after the initiation of gabapentin therapy in patients with postherpetic neuralgia. Clin Ther, November 2003.

76. Berger A, Dukes E, Smith M, Hagiwara M, Seifeldin R, Oster G.  Use of oral and transdermal opioids among patients with metastatic cancer during the last year of life. J Pain Symptom Manage, August 2003.

66. Cheville A, Chen A, Oster G, McGarry L, Narcessian E. A randomized trial of controlled-release oxycodone during inpatient rehabilitation following unilateral total knee arthroplasty. J Bone Joint Surg, May 2001.

   

Antibiotic Therapy

29. Thompson D, Huse DM, Oster G. Outcomes of cefazolin versus ceftriaxone therapy in treating lower respiratory tract infections in adults. Ann Pharmacother, December 1992.

   

Cancer

119.  Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. J Support Oncol, May 2007.

118.  Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer, May 2007.

113.  El Ouagari K, Karnon J, Delea T, Talbot W, Brandman J. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat, Jan 2007.

108.  Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, Oster G. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol, July/August 2006.

107.  Delea TE, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, Oster G. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol, July 2006.

106.  Delea TE, Karnon J, Smith RE, Johnston SRD, Brandman J, Sung JCY, Goss PE. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care, July 2006.

104.  Karnon J, Delea T, Johnston SR, Smith R, Brandman J, Sung J, Goss PE.  Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy. Pharmacoeconomics, March 2006.

103.  Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother, March 2006.

102.  Vera-Llonch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer, February 2006.

98.  Berger A, Dukes E, Mercadante S, Oster G.  Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain.  Eur J Cancer Care, October 2005.

90.  Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G.  The cost of treatment of skeletal-related events in patients with bone metasteses from lung cancer. Oncology, November 2004.

83. Berger A, Smith M, Lidsky L, Seifeldin R, Oster G. Opioid use and health care charges at the end of life in patients with metastatic cancer. Manag Care Interface, April 2004.

71. Delea TE, Vera-Llonch M, Edelsberg J, McGarry L, Anton S, Ulcickas-Yood M, Oster G. The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colon cancer. Value Health, January/February 2002.

40. Drummond M, Menzin J, Oster G. Methodologic issues in economic assessments of new therapies: The case of colony-stimulating factors. Pharmacoeconomics, 1994 (Supplement 2).

39. Oster G, Menzin J, Richard D, Cour-Chabernaud V. Overview of the lenograstim pharmacoeconomics program. Pharmacoeconomics, 1994 (Supplement 2).

38. Oster G, Menzin J, Richard D, Cour-Chabernaud V. Pharmacoeconomic evaluation of lenograstim: Conclusions and future directions. Pharmacoeconomics, 1994 (Supplement 2).

   

Cardiovascular Disease

123.  Delea TE, Taneja C, Moynahan A, Thomas SK, Frech-Tamas F, Oster G. Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension. Am J Health-Syst Pharm 2007, Jun 2007.

122.  Weycker D, Nichols GA, O’Keeffe-Rosetti M, Edelsberg J, Khan ZM, Kaura S, Oster G. Risk-factor clustering and cardiovascular disease risk in hypertensive patients. Am J Hypertens, June 2007.

99.  Delea T, Jacobson T, Serruys P, Edelsberg J, Oster G.  Cost-effectiveness of fluvastatin following successful first percutaneous coronary intervention. Ann Pharmacother, April 2005.  

92. Delea TE, Stanford R, Hagiwara M, Edelsberg JS, Oster G.  Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate.  Intl J Cardiology, March 2005.

70. Brown JB, Delea TE, Nichols GA, Edelsberg J, Elmer PJ, Oster G. Use of oral antithrombotic agents among health maintenance organization members with atherosclerotic cardiovascular disease. Arch Intern Med, January 2002.

68. Vera-Llonch MV, Menzin J, Richner R, Oster G. Cost-Effectiveness Results from the US Carvedilol Heart Failure Trials Program. Ann Pharmacother, July 2001.

67. Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN, Colucci WS, et al. Influence of carvedilol on hospitalizations in heart failure: Incidence, resource utilization and costs. J Am Coll Cardiol, May 2001.

56. Delea T, Vera-Llonch M, Richner R, Fowler MB, Oster G. The cost-effectiveness of carvedilol for heart failure. Am J Cardiol, March 1998.

33. Oster G, Huse DM, Lacey M, Epstein AM. The cost-effectiveness of ticlopidine in preventing stroke in high-risk patients. Stroke, June 1994.

32. Oster G, Borok G, Menzin J, et al. The Cholesterol-Reduction Intervention Study (CRIS) (abstract). Clin Res, April 1994.

13. Savage DD, McGee DL, Oster G. Reduction of hypertension-associated heart disease and stroke among black Americans: Past experience and new perspectives on targeting resources. Milbank Mem Fund Q, 1987.

9. Oster G, Epstein AM. The cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease: The case of cholestyramine. J Am Med Assoc, November 1987.

8. Oster G, Huse DM, Delea TE, Savage DD, Colditz GA. Cost-effectiveness of labetalol and propranolol in the treatment of hypertension among blacks. J Natl Med Assoc, October 1987.

6. Oster G, Epstein AM. Cholesterol reduction and health policy: Taking clinical science to patient care. Ann Intern Med, April 1987.

2. Oster G, Epstein AM. Primary prevention and coronary heart disease: The economic benefits of lowering serum cholesterol. Am J Public Health, June 1986.

   

Dermatologic Diseases

120.  Delea TE, Gokhale M, Makin C, Hussein MA, Vanderpoel J, Sandman T, Chang J, Sung J, Pinkston P, Gause D, Jackson JM. Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus. J Manag Care Pharm, May 2007.

Diabetes

117.  Weycker D, Edelsberg J, Vincze G, Kjeldsen SE, Jamerson K, Khan ZM, Oster G. Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. J Hum Hypertens, May 2007.

77. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS.  Use of thiazolidinesdiones and risk of heart failure in people with Type 2 diabetes. Diabetes Care, November 2003.

51. Ollendorf DA, Kotsanos JG, Wishner WJ, Friedman M, Cooper T, Bittoni M, Oster G. Potential economic benefits of lower-extremity amputation prevention strategies in diabetes. Diabetes Care, August 1998.

18. Huse DM, Oster G, Killen AR, Lacey MJ, Colditz GA. The economic costs of noninsulin-dependent diabetes mellitus. J Am Med Assoc, November 1989.

   

Drug Interactions and Side Effects

48. Thompson D, Oster G. Use of terfenadine and contraindicated drugs. J Am Med Assoc, May 1996.

23. Oster G, Huse DM, Adams SF, Imbimbo J, Russell MW. Benzodiazepine tranquilizers and the risk of accidental injury. Am J Public Health, December 1990.

10. Oster G, Russell MW, Adams SF, Imbimbo J, Huse DM. Accident- and injury-related health care utilization among benzodiazepine users and nonusers. J Clin Psychiatry, December 1987.

   

Dyslipidemia and Cholesterol

53. Oster G. The economics of hypercholesterolemia and lipid-lowering therapy: A brief historical tour. Value Health, Fall 1998.

52. Delea T. Use of surrogate measures in cost-effectiveness analyses of lipid-lowering therapies. Value Health, Fall 1998.

46. Oster G, Borok GM, Menzin, J, Heyse JF, Epstein RS, Quinn V, Benson V, Dudl RJ, Epstein AM. The Cholesterol-Reduction Intervention Study: A randomized trial to assess effectiveness and costs in clinical practice. Arch Intern Med, April 1996.

45. Oster G, Thompson D. Estimated effects of reducing dietary saturated fat intake on the incidence and costs of coronary heart disease in the United States. J Am Diet Assoc, February 1996.

36. Oster G, Borok G, Menzin J, Heys JF, Epstein RS, Quinn V, Benson VV, Dudl RJ, Epstein A. A randomized trial to assess effectiveness and cost in clinical practice: Rationale and design of the Cholesterol-Reduction Intervention Study (CRIS). Control Clin Trials, February 1995.

32. Oster G, Borok G, Menzin J, et al. The Cholesterol-Reduction Intervention Study (CRIS) (abstract). Clin Res, April 1994.

28. Glick H, Heyse JF, Thompson D, Epstein RS, Smith ME, Oster G. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment. Int J Technol Assess Health Care, Fall 1992.

26. Thompson D, Oster G. Cost-effectiveness of drug therapy for hypercholesterolemia. Pharmacoeconomics, July 1992.

   

Gastrointestinal Diseases

21. Oster G, Huse DM, Delea TE, Colditz GA, Richter JM. The risks and benefits of an Rx-to-OTC switch: The case study of over-the-counter H2-blockers. Med Care, September 1990.

17. Richter JM, Colditz GA, Huse DM, Delea TE, Oster G. Cimetidine and adverse reactions: A meta-analysis of randomized clinical trials of acute therapy. Am J Med, September 1989.

   

Hematology

116. Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients : US healthcare system perspective. Pharmacoeconomics, April 2007.

Infectious Disease

78. Weycker D, Akhras KS, Edelsberg J, Angus DC, Oster G. Long-term mortality and medical care charges in patients with severe sepsis. Crit Care Med, September 2003.

72. Ollendorf DA, Fendrick AM, Massey K, Williams GR, Oster G. Is sepsis accurately coded on hospital bills? Value Health, March/April 2002.

57. Thompson D, Oster G, McGarry LJ, Klein JO. Management of otitis media among children in a large health insurance plan. Pediatr Infect Dis J, March 1999.

35. Thompson D, Schultz N, Oster G. Comparative antifungal therapy: Outcomes and costs. P & T, August 1994.

27. Menzin J, Huse DM, Richner R, Oster G. Economic evaluation of oral ofloxacin versus standard parenteral therapy in the treatment of pneumonia. Pharmacoeconomics, August 1992.

24. Huse DM, Menzin J, Thompson D, Oster G. Inpatient outcomes research: Injectable cephalosporin therapy for pediatric pneumonia. P&T, April 1991.

   

Inflammatory Disease

100.  Berger A, Edelsberg J, Li TT, Maclean JR, Oster G.  Dose intensification with infliximab in patients with rheumatoid arthritis.  Ann Pharmacother, December 2005.

93. Weycker D, Yu EB, Woolley JM, Oster G. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged >65 years with rheumatoid arthritis. Clin Ther, May 2005.

Mental Health/Psychiatry

87. Vera-Llonch M, Delea TE, Richardson E, Rupnow M, Grogg A, Oster G. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders:  A Markov Model. Value Health, September 2004.

85. Mahmoud RA, Englehart LM, Janagap CC, Oster G, Ollendorf D.  Risperdone versus conventional antipsychotics for schizophrenia and schizoaffective disorder:  Symptoms, quality of life and resource use under customary clinical care.  Clin Drug Invest, May 2004.

54. Mahmoud R, Engelhart L, Ollendorf D, Oster G. The Risperidone Outcomes Study of Effectiveness (ROSE): A model for evaluating treatment strategies in typical psychiatric practice. J Clin Psychiatry, October 1998.

50. Thompson D, Hylan TR, McMullen W, Romeis ME, Buesching D, Oster G. Predictors of a medical-offset effect among patients receiving antidepressant therapy. Am J Psychiatry, June 1998.

49. Thompson D, Buesching D, Gregor KJ, Oster G. Patterns of antidepressant use and their relation to costs of care. Am J Manag Care, October 1996.

   

Metabolic Disorders

124. Weycker D, Nichols GA, O'keeffe-Rosetti M, Edelsberg J, Vincze G, Khan ZM, Oster G.  Risk of chronic kidney disease in hypertensive patients with other metabolic conditions. J Hum Hypertens August 2007.

    

Neurology

129.  Vera-Llonch M, Brandenburg NA, Oster G. Cost-effectiveness of Add-on Therapy with Pregabalin in Patients with Refractory Partial Epilepsy. Epilepsia October 2007. [Epub]

128.  Diaz S, Argumosa A, Horga de la Parte JF, Vera-Llonch M, Dukes E, Rejas-Gutierrez J. Análisis coste-efectividad del tratamiento de la epilepsia parcial refractaria: un modelo de simulación de pregabalina y levetiracetam. Rev Neurol October 2007.

125. Cramer JA, Brandenburg NA, Xu X, Vera-Llonch M, Oster G.   The impact of seizures and adverse effects on global health ratings.  Epilepsy Behav September 2007.

16. Killen AR, Oster G, Colditz GA. An assessment of the role of 1-123-N-isopropyl- P-iodoamphetamine in the diagnosis of stroke and Alzheimer's disease. Nucl Med Commun, February 1989.

   

Obesity

89. Elmer PJ, Brown JB, Nichols GA, Oster G.  Effects of weight gain on medical care costs.  Int J Obes Relat Metab Disord, November, 2004.

64. Thompson D, Brown JB, Nichols GA, Elmer PJ, Oster G. Body mass index and future healthcare costs: A retrospective cohort study. Obes Res, March 2001.

61. Oster G, Edelsberg J, O'Sullivan AK, Thompson D. The clinical and economic burden of obesity in a managed care setting. Am J Manag Care, May 2000.

59. Thompson D, Edelsberg J, Colditz GA, Bird AP, Oster G. The lifetime health and economic consequences of obesity. Arch Intern Med, October 1999.

58. Oster G, Thompson D, Edelsberg J, Bird AP, Colditz GA. The lifetime health and economic benefits of weight loss among persons who are obese. Am J Public Health, October 1999.

55. Thompson D, Edelsberg J, Kinsey K, Oster G. Estimated economic costs of obesity to U.S. business. Am J Health Promot, Nov/Dec 1998.

   

Oncology

130.  Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G. Cost of neutropenic complications of chemotherapy. Ann Oncol December 2007. [E-pub]

73. Bellm LA, Cunningham G, Durnell L, Eilers J, Epstein JB, Fleming T, Fuchs HJ, Haskins MN, Horowitz MM, Martin PJ, McGuire DB, Mullane K, Oster G. Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: Oral Mucositis Patient Provider Advisory Board. Cancer Invest, May/June 2002.

65. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, Hayden V, Eilers J, Epstein JB, LeVeque FG, Miller C, Peterson DE, Schubert MM, Spijkervet FK, Horowitz M. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol, April 2001.

   

Osteoporosis

115.  Weycker D, Macarios D, Edelsberg J, Oster G.  Compliance with osteoporosis drug therapy and risk of fracture.  Osteoporos Int, March 2007.

105.  Weycker D, Macarios D, Edelsberg J, Oster G.  Compliance with drug therapy for post menopausal osteoporosis.  Osteoporos Int, July 2006.

Pharmacoeconomic Methods

121.  Weycker D, Taneja C, Edelsberg J, Erder MH, Schmitt FA, Setyawan J, Oster G. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin, May 2007.

22. Huse DM, Oster G. Cost-effectiveness of drug therapy: Application of the concept: Part III. P&T, September 1990.

20. Menzin J, Oster G. Cost-effectiveness of drug therapy: Application of the concept, Part II. P&T, July 1990.

19. Thompson D, Oster G. Cost-effectiveness of drug therapy: Application of the concept, Part I. P&T, May 1990.

12. Oster G, Delea TE. Comment: Cost-effectiveness methodology. Drug Intell Clin Pharm, May 1988.

11. Oster G. Economic aspects of clinical decision making: Applications in patient care. Am J Hosp Pharm, March 1988.

   

Quality of Life

94. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: Results from a population-based survey. J Pain, June 2005.

82. Manco-Johnson M, Morrissey-Harding G, Edelman-Lewis B, Oster G, Larson P.  Development and validation of a measure of disease-specific quality of life in young children with haemophilia. Haemophilia, March 2004.

37. Cleary P, Morrissey G, Yver A, Oster G. The effects of rG-CSF on health-related quality of life in children with congenital agranulocytosis. Qual Life Res, November 1994.

25. Cleary PD, Epstein AM, Oster G, Morrissey GS, Stason WB, Debussey S, Plachetka J, Zimmerman M. Health-related quality of life among patients undergoing percutaneous transluminal coronary angioplasty. Med Care, September 1991.

   

Respiratory Diseases

110.  Raghu G, Weycker D, Eelsberg J, Bradford WZ, Oster G.  Incidence and prevalence of idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med, October 2006.

97.  Weycker D, Edelsberg J, Oster G, Tino G.  Prevalence and economic burden of bronchiectasis.  Clin Pulm Med, July 2005

96. Martines FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK; IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis.  Ann Intern Med, June 2005.

75. Rello J, Ollendorf DA, Oster G, Vera-Llonch M, et al.  Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest, December 2002.

60. Ollendorf D, McGarry L, Watrous M, Oster G. Use of rhDnase therapy and costs of respiratory-related care in patients with cystic fibrosis. Ann Pharmacother, March 2000.

44. Menzin J, Oster G, Davies L, Drummond M, et al. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis. Int J Technol Assess Health Care, Winter 1996.

42. Oster G, Huse DM, Lacey M, Regan MM, Fuchs HJ. Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. Ann Pharmacother, May 1995.

   

Rheumatology

126. Berger A, Dukes E, Martin S, Edelsberg J, Oster G. Characteristics and healthcare costs of patients with fibromyalgia syndrome.  Int J Clin Pract. September 2007.

Smoking Cessation

47. Oster G, Delea TE, Huse DM, Regan MM, Colditz GA. The benefits and risks of over-the-counter availability of nicotine polacrilex ('nicotine gum'). Med Care, May 1996.

15. Cummings SR, Rubin SM, Oster G. The cost-effectiveness of counseling smokers to quit. J Am Med Assoc, January 1989.

14. Oster G, Delea TE, Colditz GA. Maternal smoking during pregnancy and expenditures of neonatal health care. Am J Prev Med, July/August 1988.

4. Oster G, Delea TE, Huse DM, Colditz GA. The cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. J Am Med Assoc, September 1986.

1. Oster G, Colditz GA, Kelly NL. The economic costs of smoking and benefits of quitting for individual smokers. Prev Med, July 1984.

   

Urology

63. Oster G, Edelsberg J, Pozniak A, Thompson D. Resource utilization and costs of treatment with doxazosin versus tamsulosin in men with benign prostatic hyperplasia. J Outcomes Res, December 2000.

43. Cleary P, Harding GM, Oster G, Health-related quality of life in patients with advanced prostate cancer: A multi-national perspective. Qual Life Res, June 1995.

30. Weis K, Epstein RS, Huse DM, Deverka, P, Oster G. The costs of prostatectomy for benign prostatic hyperplasia. Prostate, June 1993.

   

Vaccines

91. Weycker D, Edelsberg J, Halloran ME, Longini IM Jr, Nizam A, Ciuryla V, Oster G.  Population-wide benefits of routine vaccination of children against influenza. Vaccine, January 2005.

62. Weycker D, Richardson E, Oster G. Childhood vaccination against pneumococcal otitis media and pneumonia: An analysis of benefits and costs. Am J Manag Care, July 2000.

34. Huse DM, Meissner HC, Lacey MJ, Oster G. Childhood vaccination against chickenpox: An analysis of benefits and costs. Journal Pediatr, June 1994.

   

Venous Thromboembolism

111.  Edelsberg J, Hagiwara M, Taneja C, Oster G.  Risk of venous thromboembolism among hospitalized medically ill patients.  Am J Health-Syst Pharm, October 2006.

86. Sullivan SD, Davidson BL, Kahn SR, Muntz JE, Oster G, Raskob G.  A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboemboslism: Use in patients undergoing major orthopaedic surgery.  Pharmacoeconomics, September 2004.

80. Oster G, Ollendorf DA, Vera-Llonch M, Hagiwara M, Berger A, Edelsberg J. Economic consequences of venous thromboembolism following major orthopedic surgery. Ann Pharmacother, March 2004.

74. Ollendorf DA, Vera-Llonch M, Oster G.  Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients.  Am J Health-Syst Pharm, September 2002.

69. Edelsberg J, Ollendorf D, Oster G.  Venous thromboembolism following major orthopedic surgery: Review of epidemiology and economics. Am J Health-Syst Pharm,  November 2001.

41. Menzin J, Colditz G, Regan M, et al., Cost-effectiveness of enoxaparin versus low-dose warfarin in the prevention of venous thromboembolism following total hip replacement surgery. Arch of Intern Med, April 1995.

31. Menzin J, Richner R, Huse DM, Colditz GA, Oster G. Prevention of deep-vein thrombosis following total-hip replacement surgery with enoxaparin versus unfractionated heparin: A pharmacoeconomic evaluation. Ann Pharmacother, February 1994.

7. Oster G, Tuden RL, Colditz GA. Prevention of venous thromboembolism after general surgery: A cost-effectiveness analysis of alternative approaches to prophylaxis. Am J Med, May 1987.

5. Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-vein-thrombosis in major orthopedic surgery. J Am Med Assoc, January 1987.